Alimera Sciences (ALIM) FDA Approvals

Alimera Sciences' Drug in the FDA Approval Process

This section highlights FDA-related milestones and regulatory updates for drugs developed by Alimera Sciences (ALIM). Over the past two years, Alimera Sciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as ILUVIEN®. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend.

ILUVIEN® FDA Regulatory Timeline and Events

ILUVIEN® is a drug developed by Alimera Sciences for the following indication: For patients with diabetic macular edema. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy.

Provided Update - December 2,2025

• Drug: ILUVIEN®
• Announced Date: December 2, 2025
• Indication: For patients with diabetic macular edema

ANI Pharmaceuticals, Inc. announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company's Rare Disease business.

ANI Pharmaceuticals has formed The FutureVision Advisory Council to guide the strategic growth of its ophthalmology and retina franchise within the company’s Rare Disease business. The council includes ten globally recognized clinicians — seven retina specialists and three uveitis specialists — and is co‑led by Arshad M. Khanani, MD (Principal Retina Advisor and Chair), and Peter Y. Chang, MD (Principal Uveitis Advisor and Chair). ANI says the group will help shape strategy for existing products and advise the development of new treatments to better serve patients.

Company leadership described the council as an important step to expand the franchise and improve patient outcomes. Members bring decades of experience in clinical research, innovation, and patient care, and will advise on clinical priorities, trial design, and commercialization opportunities for ANI’s ophthalmology portfolio, which includes ILUVIEN and Cortrophin Gel.

Results - July 23,2025

• Drug: ILUVIEN®
• Announced Date: July 23, 2025
• Indication: For patients with diabetic macular edema

ANI Pharmaceuticals, Inc. announced results from the NEW DAY clinical trial of ILUVIEN® (fluocinolone acetonide intravitreal implant), 0.19 mg (ILUVIEN) for use in patients with diabetic macular edema (DME).

At the ASRS meeting, ANI Pharmaceuticals presented results from the NEW DAY trial in over 300 DME patients. The primary endpoint measured mean supplemental aflibercept injections over 18 months: ILUVIEN patients needed 2.4 injections versus 2.5 for aflibercept (p=0.756), missing significance.

The time to first supplemental injection was significantly longer with ILUVIEN (185.4 days vs. 132.8 days, p<0.001). In post-hoc analysis of a strict protocol subgroup, ILUVIEN required fewer supplemental injections (1.8 vs. 2.5, p=0.029). Thirty-three percent of ILUVIEN patients avoided extra injections, compared to 30 percent in the aflibercept arm.

Dr. Singer noted DME’s multifactorial nature and highlighted ILUVIEN’s potential to reduce treatment visits. The implant’s safety profile was consistent with earlier studies, with expected cataract and intraocular pressure increases. ANI’s CEO said these data may support earlier ILUVIEN use to lower treatment burden in diabetic macular edema.

FDA Approval - March 14,2025

• Drug: ILUVIEN®
• Announced Date: March 14, 2025
• Indication: For patients with diabetic macular edema

ANI Pharmaceuticals, announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant) that includes an indication for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS).

ANI Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved an expanded label for ILUVIEN (fluocinolone acetonide intravitreal implant). This new approval includes a treatment indication for chronic non-infectious uveitis affecting the posterior segment of the eye (NIU-PS), in addition to its existing use for diabetic macular edema (DME). With this label expansion, ILUVIEN now offers an additional, long-acting treatment option for patients suffering from NIU-PS. ANI plans to begin marketing the product in the United States under the combined indications later this year. The updated label also features revisions in the warnings and precautions sections to guide safe administration. This decision by the FDA strengthens the treatment options available for patients with these chronic eye conditions while expanding the clinical reach of ILUVIEN in the U.S. market.

Alimera Sciences FDA Events - Frequently Asked Questions

Has Alimera Sciences received FDA approval?

As of now, Alimera Sciences (ALIM) has not received any FDA approvals for its therapy in the last two years.

What drugs has Alimera Sciences submitted to the FDA?

In the past two years, Alimera Sciences (ALIM) has reported FDA regulatory activity for ILUVIEN®.

What is the most recent FDA event for Alimera Sciences?

The most recent FDA-related event for Alimera Sciences occurred on December 2, 2025, involving ILUVIEN®. The update was categorized as "Provided Update," with the company reporting: "ANI Pharmaceuticals, Inc. announced that it has established The FutureVision Advisory Council to help guide the strategic advancement of its ophthalmology and retina franchise within the Company's Rare Disease business."

What conditions do Alimera Sciences' current drugs treat?

Currently, Alimera Sciences has one therapy (ILUVIEN®) targeting the following condition: For patients with diabetic macular edema.